6885 Share Price Performance
NT$28.95
-3.10 (-9.67%)
Price NT$28.95
Share Pricen/a
BRIM Biotechnology, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6885 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
BRIM Biotechnology, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.91
- 42.59%
- -12,222.57%
- 0.6%
About 6885
- Founded
- 2013
- Employees
- 32
- CEO
- WebsiteView website
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
